Source: International Congress 2014 – COPD markers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Storgaard, M. Frystyk, H. Hockey, U. M. Weinreich (Aalborg, Denmark; Hamilton, New Zealand). Number of exacerbations in COPD patients treated with nasal high flow heated and humidified oxygen. Eur Respir J 2014; 44: Suppl. 58, 4730

Member's Comments

No comment yet.

Related content which might interest you: Effect of nasal high flow heated oxygen in chronic airway disease on quality of life and hospital admissions Source: International Congress 2016 – Latest insights into the management of chronic respiratory diseases Year: 2016 The influence of complex ICS/LABA therapy on oxygen consumption in COPD patients Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Long-term nasal high flow treatment with oxygen in COPD - exacerbations, admissions and mortality Source: International Congress 2017 – Best abstracts in physical activity and management of COPD Year: 2017 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013 Impact of frequent exacerbations in patients with COPD Source: International Congress 2014 – Clinical presentations Year: 2014 Evolution of COPD patients with exertional desaturation treated with long term oxygen therapy during one year Source: International Congress 2014 – COPD physiopathology Year: 2014 Clinical characteristics of patients with clinically-diagnosed COPD exacerbations but without concomitant airflow limitation Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Identification of nasal virus infection in patients with COPD exacerbations Source: International Congress 2014 – COPD: points to ponder Year: 2014 Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Resting heart rate and exacerbations in COPD patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016